Medtronic makes 3 MiniMed 780G Announcements

Medtronic has announced 3 milestones that broaden MiniMed 780G's hybrid-closed loop system in the USA. The news covers Medicare access, new insulin options, and an expansion to people with insulin-requiring type 2 diabetes.

Medicare access with Abbott CGM

In the US, people covered by Medicare and Medicare Advantage can now access the MiniMed 780G when paired with the Instinct sensor. The Instinct sensor offers up to 15 days of wear and adds another CGM option alongside Medtronic’s own Simplera Sync and Guardian 4 sensors.

For Medicare users, this expands sensor choice within a hybrid-closed loop system that automatically adjusts insulin delivery every five minutes, aiming to reduce time spent high or low and lower the day-to-day burden of decision-making.

Ultra-rapid insulin clearance

The MiniMed 780G has also been cleared by the Food and Drug Administration for use with ultra-rapid acting insulins Fiasp and Lyumjev.

These faster insulins are designed to act more quickly around meals and may help limit the impact of late or missed boluses. When combined with Medtronic’s Meal Detection technology, the update gives clinicians and users more flexibility to tailor therapy to eating habits and lifestyle.

Type 2 diabetes clearance

In a further expansion, the FDA has cleared the MiniMed 780G system for use with the Instinct sensor in people with insulin-requiring type 2 diabetes. This clearance recognises the SmartGuard algorithm as an interoperable automated glycaemic controller and the pump as an alternate controller enabled device, allowing integration with Abbott’s CGM.

For people with type 2 diabetes who require insulin, this opens access to a hybrid-closed loop system that can automatically adjust insulin delivery throughout the day and provide support when meal doses are missed or underestimated.

What this means

Taken together, these milestones signal a continued push in the US towards wider access, more CGM choice, and greater flexibility within hybrid-closed loop systems. While the announcements apply to the American market, they will be watched closely elsewhere as companies continue to expand interoperability between pumps, CGMs, and insulin options.

________

Disclaimer

Blogs and publications on this website are independent of any involvement by medtech companies or diabetes related charities. To ensure there is no bias, we do not accept any products, freebies or other material from any medtech provider. Except where credited otherwise, all materials are copyright ©️What CGM.

What CGM is not associated or affiliated with Abbott or FreeStyle Libre. Content here and on our websitewww.whatcgm.com does not constitute medical advice or replace the relationship between you and healthcare professionals nor the advice you receive from them.

The author of this blog has type 1 diabetes and uses a CGM on NHS prescription.